Miriam, 35, has a tumor with two sides that Spanish protocols don't account for. The tests she needs to treat it aren't covered by public healthcare. This site exists to fund them.
Every euro funds clinical research applied to her case.
Open the full molecular profile in The science.
Already supported by 970 people · featured in El País
Latest· updated 11 days agoA new scan opens another door€38,166
raised so far
970
people have contributed
5+
specialists in 3 countries
80%
neuroendocrine differentiation
The story
At 33, Miriam was diagnosed with a metastatic breast cancer so rare it is seen in fewer than 1 in 1,000 cases. The standard treatment isn't enough: it has to be designed around her specific tumor.
Source: SEER population analysis · Transl. Cancer Res., 2023
Get to know Miriam (soon)In her own words
«My tumor has two sides —the breast side and the neuroendocrine one— and the key is to treat both at once, not just one.»
— Miriam González. May 2026.
Clinical gap
Spanish protocols only account for half of the tumor's biology: they're built for standard HR+ breast cancer, and Miriam's is not.
In practice: hormonal treatment addresses the tumor's side but leaves its component untreated. Confirming and targeting it requires molecular rebiopsy and international expert review — tests public healthcare doesn't cover for such a rare case.
Tap or hover the highlighted words and markers to see what they mean.
What the protocols cover
What is missing and not covered
What the protocols cover
What is missing and not covered
Full technical analysis in The science. The essential point: a measurable gap exists between the treatment she receives and the one her biology requires.
Where this is heading
An trial is a clinical trial built for a single patient: treatment is designed around her tumor's actual profile, not an average protocol. That makes it possible to combine drugs to target its two sides at once — the luminal (breast) one and the possible neuroendocrine one.
The advantages of reaching that trial:
In one line, for anyone who wants the detail:
Those with “?” are hypotheses with partial evidence, pending confirmation. Full analysis in The science.
Open clinical documentation. Updated in 2026.
Where the money goes · Radical transparency
The tumor evolves under treatment pressure. New resistance mutations appear (ESR1 D538G, RB1) and new targets emerge (SSTR2+). Without periodic molecular rebiopsy, clinical decisions are made blind.
Every euro is assigned to a concrete line item and documented on the Expenses page.
The money goes to:
Three ways to contribute · Pick yours
01
Getting the case in front of whoever can move it forward —in oncology, research or among patients— is often the difference between finding a therapeutic target and not finding one.
Share the site with whoever can move the case forward.
02
Understand the full molecular profile, the active biological hypotheses and the compatible clinical trials. Open, reviewed documentation.
Read the molecular profileNo sign-up, no paywall.
03
Every euro funds research applied to the case: deep sequencing, molecular rebiopsy, international second opinions, N-of-1 trial.
Support MiriamSecure payment. Receipt available. 100% to Miriam's case.
High-impact profiles
Are you a doctor, researcher or journalist?
There's a direct door for you.
Campaign status · Real time